Skip to main content

Table 3 Comparison of baseline mean for weight, BMI, glucose indices, nesfatin, inflammatory factors, and liver enzymes in overweight/obese patients with non-alcoholic fatty liver disease (NAFLD)

From: Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial

Variables Nanocurcumin (n = 42) Mean(SD) Placebo (n = 42) Mean(SD) P-value
Weight (kg) 86.54(10.98) 86.70(11.15) 0.9*
BMI (kg/m2) 30.67(2.14) 30.75(2.35) 0.9**
Waist circumference (cm) 105.4(6.2) 103.8(6.7) 0.8*
Fat Mass (%) 31.6(6.4) 31.9(4.7) 0.8*
SBP (mmhg) 120.3(4.7) 120.7(4.3) 0.7**
DBP (mmhg) 78.8(4.5) 79.8(4.3) 0.1*
ALT (u/l) 42.8(11.6) 42.1(8.2) 0.7**
AST (u/l) 28.4(6.7) 27.6(7.8) 0.4**
TC (mg/dl) 212.9(18.9) 211.8(21.4) 0.8*
LDL-c (mg/dl) 135.6(17.6) 133.0(20.7) 0.6*
TG (mg/dl) 175.9(70.3) 181.2(65.6) 0.7**
HDL-c (mg/dl) 41.8(5.6) 42.7(5.7) 0.4*
FBS (mg/dl) 89.1(5.4) 89.3(5.8) 0.9*
HbA1c (%) 5.2(0.2) 5.3(0.2) 0.4**
Nesfatin (ng/ml) 1.8(0.5) 1.8(0.4) 0.5*
FBI (μIU/ml) 8.0(0.5) 7.9(0.6) 0.7*
TNF-α (ng/l) 14.7(3.3) 15.1(2.7) 0.2*
IL-6 (ng/l) 7.6(1.5) 7.9(1.5) 0.2*
hs-CRP (mg/l) 5.9(2.5) 5.3(2.5) 0.2**
HOMA-IR (score) 1.77(0.16) 1.75(0.17) 0.7**
QUICKI (score) 0.3505(0.0049) 0.3509(0.0057) 0.7*
  1. *t-test; **Mann-Whitney; ALT alanine transaminase, AST aspartate transaminase, BMI body mass index, FBI fasting blood insulin,FBS fasting blood sugar, HOMA-IR homeostasis model assessment-insulin resistance, hs-CRP high-sensitive C-reactive protein, HDL-C high density lipoprotein-cholesterol, IL-6 interleukin-6, LDL-C low density lipoprotein-cholesterol, QUICKI quantitative insulin sensitivity check index, TC total cholesterol, TNF-α tumor necrosis factor-alpha